Matthew Seymour, MD: A Clinical Trialist’s Perspective

Leonard B. Saltz, MD, of Memorial Sloan Kettering Cancer Center, discusses interventional pharmacoeconomics as an important tool that can offer patients with cancer more efficacious and cost-effective care. Pharmacoeconomics may help reduce the high costs of cancer therapy, with evidence-based reductions in doses that maintain effective treatment.

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Lymphoma

The ASCO Post Staff

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

Mark J. Ratain, MD, of the University of Chicago, talks about why ibrutinib—which can lead to cardiotoxicities—should be studied at a lower dose for patients with chronic lymphocytic leukemia. Data suggest a reduced dose may prevent dose interruption due to adverse events and may have a better therapeutic index.

Jul

Today In Oncology

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Related Videos

Opportunities to Optimize Cancer Policies Panel Discussion

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

Does Bilateral Mastectomy for Unilateral Breast Cancer Impact Mortality

Patients With Prostate Cancer Social Factors May Be Tied to Racial Disparities in Cardiovascular Outcomes

Update on LEANer Trial in Patients With Breast Cancer

Triplet as Initial Salvage Treatment for Advanced Germ Cell Tumors Long-Term Outcomes

New Study Highlights Improvements in Treating Pediatric Patients With Retinoblastoma